Angiotensin-Converting Enzyme Inhibitors
Scientific Basis for Clinical Use
2nd Edition
Published on 29. March 1995
Book
Paperback/Softback
309 pages
978-0-471-11195-5 (ISBN)
Description
About the Book ACE inhibitors are justly regarded as the most important advance in cardiac drug therapy since the advent of calcium channel antagonist drugs. Acting basically as inhibitors of the renin-angiotensin vasoconstrictor system, these agents have grown in importance to become among the therapeutic agents first choice for hypertension and a cornerstone of therapy in congestive heart failure. Recent studies show that they can also prevent overt heart failure and reinfarction, and beneficially influence diabetic renal lesions. The major aim of Angiotensin-Converting Enzyme Inhibitors: Scientific Basis for Clinical Use is to present the clinician with the information needed for the practical and discerning use of ACE inhibitors. When do these agents really work and in what doses? Which claims are based on promotional material and which claims have relevance for the clinician in the practical treatment of hypertension, heart failure or myocardial infarction? This Second Edition adds new material that critically reviews the recent large trials including Consensus-II, Save, V-HeFT-II, Aire, and ISIS-IV and guides the clinician toward a rational policy of use. There is an important new chapter on the use of ACE inhibitors in the metabolic cardiovascular syndrome and in diabetic nephropathy. Reviews of Other Books by the Author Drugs for the Heart--"A gem" (New England Journal of Medicine) The Heart--"The subjects are brilliantly illuminated and made exciting by excellent line diagrams" (The Lancet) Reviews of First Edition of this Book "A new milestone" (British Medical Journal) "Pathophysiology is clarified by numerous diagrams in a style well-known from Opie's former books" (The Lancet)
More details
Edition
2nd edition
Language
English
Place of publication
New York
United States
Publishing group
John Wiley & Sons Inc
Target group
Professional and scholarly
Dimensions
Height: 253 mm
Width: 120 mm
Thickness: 15 mm
Weight
482 gr
ISBN-13
978-0-471-11195-5 (9780471111955)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Previous edition
Book
05/1992
Wiley
€39.00
Article exhausted; check for reprint
Person
Lionel H. Opie, M.D., Ph.D., is Professor of Medicine at the University of Cape Town. After graduating from the University of Cape Town, he studied at Oxford as a Rhodes Scholar and was a Research Fellow at Harvard from 1959-1961. He became a Fellow of the Royal College of Physicians of London in 1974. From 1976-1978, he was President of the International Society for Heart Research. He is the author of The Heart: Physiology and Metabolism, Second Edition, 1991, and Myocardial Protection by Calcium Antagonists, 1994. He is Editor of Drugs for the Heart, Fourth Edition in preparation for 1995. He is Co-Editor of Cardiovascular Drugs and Therapy. For 1990-1993, he was Chairman of the Committee on Cardiovascular Drugs of the International Society and Federation of Cardiology. In 1992, he was Visiting Professor and British Heart Foundation Senior Fellow, St. Thomas' Hospital, London. For 1984-1994, he was Visiting Professor, Division of Cardiovascular Medicine, Stanford University Medical Center, California.
Content
The Renin-Angiotensin-Aldosterone System and Other Proposed Sitesof Action of Angiotensin Converting Enzyme Inhibitors.
ACE Inhibitors for Hypertension.
ACE Inhibitors and the Kidney.
ACE Inhibitors and the Heart.
ACE Inhibitors for Congestive Heart Failure.
ACE Inhibitors and the Central Nervous System.
ACE Inhibitors: Specific Agents: Pharmacokinetics.
ACE Inhibitors: Side-Effects and Contraindications.
ACE Inhibitors: Drug Combinations and Interactions.
ACE Inhibitors, Vascular Structure, and Arterial Disease inHypertension.
ACE Inhibitors, Coronary Artery Disease, Ischemia, Arrhythemias,and Postinfarct Protection;
Other Preventative Studies.
ACE Inhibitors and Metabolic Cardiovascular Syndrome;
Diabetic Nephropathy;
Ageing.
Appendices.
Index.
ACE Inhibitors for Hypertension.
ACE Inhibitors and the Kidney.
ACE Inhibitors and the Heart.
ACE Inhibitors for Congestive Heart Failure.
ACE Inhibitors and the Central Nervous System.
ACE Inhibitors: Specific Agents: Pharmacokinetics.
ACE Inhibitors: Side-Effects and Contraindications.
ACE Inhibitors: Drug Combinations and Interactions.
ACE Inhibitors, Vascular Structure, and Arterial Disease inHypertension.
ACE Inhibitors, Coronary Artery Disease, Ischemia, Arrhythemias,and Postinfarct Protection;
Other Preventative Studies.
ACE Inhibitors and Metabolic Cardiovascular Syndrome;
Diabetic Nephropathy;
Ageing.
Appendices.
Index.